Abbvie (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN recently announced a definitive agreement for AbbVie to acquire ImmunoGen and its flagship oncology therapy ELAHERE® (mirvetuximab soravtansine-gynx). The therapy is the first antibody drug conjugate (ADC) of its kind and has been approved for the treatment of platinum-resistant ovarian cancer (PROC). The purchase price is $31.26 per share, for a total of $10.1 billion. The acquisition accelerates AbbVie's commercial and clinical research footprint in solid tumors. In addition, ImmunoGen's promising pipeline of next-generation ADC follow-on products will further enrich AbbVie's ADC platform and existing programs.

Abbvie announced that it has entered into a definitive agreement with Cerevel Therapeutics to acquire Cerevel Therapeutics for $45 per share in cash, with a total equity value of approximately $8.7 billion. Upon completion of the acquisition, AbbVie will gain access to Cerevel Therapeutics' strong neuroscience pipeline, including potential drug candidates for the treatment of schizophrenia, Parkinson's disease and mood disorders.